Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Director Sells $50,812.50 in Stock

Key Points

• Director Kathy Hibbs sold 6,250 SOPHiA GENETICS shares for approximately $50,812 at an average price of $8.13 under a pre-arranged Rule 10b5-1 trading plan, reducing her holdings by 6.05% to 96,992 shares.
• SOPH shares traded down 0.9% to $7.61, while the company reported a quarterly loss of $0.26 per share—worse than estimates—despite revenue of $23.31 million exceeding expectations.
• Analyst sentiment is mixed, with three Buy, one Hold, and one Sell rating; the consensus rating is Hold with an average price target of $10.00.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) Director Kathy Hibbs sold 6,250 shares of the company's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $8.13, for a total value of $50,812.50. Following the transaction, the director directly owned 96,992 shares of the company's stock, valued at approximately $788,544.96. This represents a 6.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

SOPHiA GENETICS Stock Down 0.9%

Shares of NASDAQ SOPH traded down $0.07 during midday trading on Thursday, hitting $7.61. 378,522 shares of the company's stock were exchanged, compared to its average volume of 261,546. The firm's fifty day simple moving average is $6.93 and its 200-day simple moving average is $5.65. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The company has a market cap of $638.40 million, a PE ratio of -6.62 and a beta of 0.98. SOPHiA GENETICS SA has a twelve month low of $3.10 and a twelve month high of $8.98.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to analysts' expectations of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. Research analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

A number of large investors have recently bought and sold shares of the business. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS in the second quarter valued at about $9,809,000. Sei Investments Co. purchased a new position in shares of SOPHiA GENETICS during the first quarter worth about $1,772,000. Maven Securities LTD acquired a new position in SOPHiA GENETICS in the 2nd quarter valued at about $866,000. 1492 Capital Management LLC purchased a new stake in SOPHiA GENETICS during the 4th quarter valued at approximately $973,000. Finally, Royce & Associates LP acquired a new stake in SOPHiA GENETICS during the 4th quarter worth approximately $2,009,000. Institutional investors and hedge funds own 31.59% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on SOPH shares. HC Wainwright upped their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research boosted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Finally, Zacks Research raised SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.